| pubmed-article:16870552 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16870552 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:16870552 | lifeskim:mentions | umls-concept:C0052416 | lld:lifeskim |
| pubmed-article:16870552 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16870552 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:16870552 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16870552 | pubmed:dateCreated | 2006-8-3 | lld:pubmed |
| pubmed-article:16870552 | pubmed:abstractText | We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL. | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16870552 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16870552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16870552 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16870552 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16870552 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:LitzowMark... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:DewaldGordon... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:TallmanMartin... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:GallagherRobe... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:MazzaJoseph... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:BennettJohn... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:LeeSandraS | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:JainVibhaV | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:RacevskisJani... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:PaiettaElisab... | lld:pubmed |
| pubmed-article:16870552 | pubmed:author | pubmed-author:RouseySteven... | lld:pubmed |
| pubmed-article:16870552 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16870552 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:16870552 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16870552 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16870552 | pubmed:pagination | 1105-8 | lld:pubmed |
| pubmed-article:16870552 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:meshHeading | pubmed-meshheading:16870552... | lld:pubmed |
| pubmed-article:16870552 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16870552 | pubmed:articleTitle | A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. | lld:pubmed |
| pubmed-article:16870552 | pubmed:affiliation | Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA. litzow.mark@mayo.edu | lld:pubmed |
| pubmed-article:16870552 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16870552 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:16870552 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16870552 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:16870552 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16870552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16870552 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16870552 | lld:pubmed |
